Document is current
Any future updates will be listed below
-
Authors
Luque, Maria
Matic, Magdalena
Heras-Garvin, Antonio
Amo-Aparicio, Jesus
Luk, Kelvin C.
Haindl, Michaela Tanja
Khalil, Michael
Skouras, Damaris B.
Dinarello, Charles A.
Stefanova, Nadia https://orcid.org/0000-0001-8188-639X
-
Funding
Funding for this research was provided by:
Michael J. Fox Foundation for Parkinson's Research (MJFF-022681)
- License Information
-
More Information
Article History
Received: 7 November 2025
Accepted: 25 January 2026
First Online: 31 January 2026
Declarations
:
: All in vivo experiments were performed according to the ARRIVE guidelines with the permission of the Austrian Federal Ministry of Science and Research (BMFWF-2022-0.429.387).
: Not applicable.
: ML, declares no competing interests.MM, declares no competing interests.AHG, declares no competing interests.JAA, declares no competing interests.KCL, declares no competing interests.MTH, declares no competing interests.MK, has received travel funding and speaker honoraria from Bayer, Biogen, Novartis, Merck, Sanofi, Roche and Teva, serves on scientific advisory boards for Biogen, Bristol-Myers Squibb, Gilead, Merck, Neuraxpharm, Novartis, Alexion, Amgen and Roche and as a consultant for Roche. He received research grants from the Austrian MS Society, Biogen, Novartis and Roche.DBS, Chief Executive Officer of Olatec Therapeutics.CAD, Chairman of Olatec’s Scientific Advisory Board, co-Chief Scientific Officer, receives compensation, and has equity in Olatec.NS, Director-at-large, Board of Directors and Chair of the Research Steering Council of Mission MSA, USA; Advisory board, Karl Golser Foundation, Italy; Advisory services for IONIS, Mitsubishi Pharma.
